Nano Mobile Healthcare Inc (VNTH)

[beer$$money]

He Jack got something huge for ya! Been looking into the details with Nanobeak & James Katzaroff's Nanomobile & following all documented connections & relationships:) Trying to bring all the dots together Gotta say its a very interesting story!!

Hint: Cancer Clinical Trial Completed!!

Official Title: NanoSpectrometer Biomarker Discovery and Confirmation Study
Actual Study Start Date : September 5, 2017
Actual Primary Completion Date : July 6, 2020
Actual Study Completion Date : July 6, 2020

Full Study Posted below links on all the connections!

Nanobeak Biotech
Biotechnology New York, New York

Mobile non-invasive disease detection at the earliest stages.

Nanobeak is operating with the goal of dominating key commercial business sectors derived from NASA technology. Applications will primarily be in life sciences industry. Our relationships with NASA enable us to opportunistically capture emerging technologies and take them to market. Nanobeak will offer products for each market segment and maintain a fully functioning global presence.

Space Act Agreements (abbreviated SAA) are a type of legal agreement specified in the National Aeronautics and Space Act of 1958 (and subsequent congressional authorizations) that uniquely empowers NASA to work with any entity that enables fulfillment of the Administration's mandate
https://en.wikipedia.org/wiki/Space_Act_Agreement


Reimbursable Agreements - Agreements where NASA's costs associated to the activity are reimbursed by the Agreement Partner (in full or in part).
NASA undertakes Reimbursable Agreements when it has unique goods, services, and facilities that are not currently being fully utilized to accomplish mission needs. These may be made available to others on a noninterference basis and consistent with the Agency's missions and policies.

59 28072 NANOBEAK, LLC Reimbursable Space Act Agreement with Nanobeak, LLC
for Development of Gas Sensor Technology 11/15/2018 11/15/2020 Reimbursable
https://www.nasa.gov/sites/default/files/atoms/files/house_approps_quarterly_report_domestic_nonfed_saas_active_as_of_3_31_2019_v2.pdf

VNTH
Nano Mobile Healthcare, Inc.
COMPANY DIRECTORS
Robert Chicoski
CFO, Interim CEO
James C. Katzaroff
Edward Rollins



https://www.otcmarkets.com/stock/VNTH/profile


FORM 10-K

[X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended June 30, 2015

Nano Mobile Healthcare, Inc.

Item 1. Business

Company Overview

We were incorporated in the State of Nevada on April 21, 2010. We were initially in the business of becoming a pharmaceutical manufacturer with the specific intention of bidding on South African government health care contracts and tenders. We abandoned that business plan when, on November 7, 2013, Nanobeak, LLC, a Delaware limited liability company (formerly Nanobeak, Inc., a California corporation) (“Nanobeak”) acquired a majority interest in our company through the stock purchase of a controlling interest in our company from Bayview Terrace Limited.

Since the change of control, we have implemented a new business plan. On January 1, 2014, Nanobeak entered into a License Agreement (the “License Agreement”) with the National Aeronautics and Space Administration (“NASA”) pursuant to which Nanobeak was granted a royalty-bearing, non-transferable license (the “License”) to certain inventions and patent rights owned by NASA relating to chemical sensing nanotechnology, for use within the United States and its territories.

The License is effective as of December 31, 2013 and subject to an initial five year term, during which the License will be exclusive to Nanobeak. Following the initial five-year term, the License shall automatically convert to a non-exclusive license. Under the License, Nanobeak is required to develop and commercialize the licensed patents. NASA provided no warranties under the License Agreement and assumed no responsibility for our use, sale or other disposition of the licensed technology. Nanobeak has agreed to indemnify NASA against all liabilities arising from such use, sale or other disposition.

Pursuant to Section 3.1.1 of the License Agreement, Nanobeak is permitted to sublicense its rights under the License Agreement to subcontractors. Effective as of February 20, 2014, Nanobeak has sublicensed such rights to us as set forth in a Sublicense Agreement.

The Sublicense Agreement grants patent rights to us on the same terms as such rights have been granted to Nanobeak under the License Agreement; provided, however, that the field of use for the patent rights granted to us is limited to disease detection.

We must pay to Nanobeak certain royalties in connection with the Sublicense Agreement, which royalties are equivalent to those owed by Nanobeak to NASA pursuant to the License Agreement. We must further comply with other obligations of Nanobeak under the License Agreement as though we were a party thereto, including achievement of practical application of the patent rights and certain reporting obligations.

The Sublicense Agreement will terminate upon the earlier of (i) termination of the License Agreement or (ii) termination by either party to the Sublicense Agreement as set forth therein.

As a result of the License Agreement and Sublicense Agreement, we are now a mobile health technology company that is developing personalized and point-of-care screening using applications based upon chemical sensing methods.

We have been developing a low cost point-of-care screening device that will detect and analyze common components from human breath and provide an early indication of chronic diseases such as heart failure and various forms of cancer, as well as contagious diseases such as strep throat. The principles of operation are driven by technology developed by NASA. The sensor can connect via Bluetooth to any capable smart device running an iOS or Android operating system. Development efforts on the sensor were concluded and the device is now in a clinical environment. The final development stage for the healthcare sensor will be formal clinical trials and ultimately to obtain FDA approval.

The current Breathalyzer has a small footprint and can easily be operated by anyone with minimal instruction. State-of-the art engineering design techniques, advanced nanotechnology, and bio-informatics have been combined to create the following three main pieces of the device that is now being used to collect sample data from test patients for certain key biomarkers in a clinical setting:
1. Breath Capture Device
2. Sensor Module
3. App/Software for the Smart Devices

We have entered into a Strategic Partnership with Scripps Translational Sciences Institute (STSI) to assist in the development, advancement, and commercialization of the mobile technology. Scripps will also provide the testing, evaluation, and detection of certain combinations of Volatile Organic Compounds (VOCs) known as the breath signature and will assist in managing our clinical trials in partnership with several other research hospitals in the United States.
10K Link:

https://www.sec.gov/Archives/edgar/data/1497130/000149315215004781/form10-k.htm

Vantage Health and Scripps Translational Science Institute form Strategic Partnership for Mobile Health Technology February 10, 2014 10:04 AM

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Vantage Health Inc. (OTCQB:VNTH) and its parent company Nanobeak Inc. today announced that they have formed a strategic partnership with Scripps Translational Science Institute (STSI) for the advancement of mobile health technology.

“This kind of collaboration is essential for the testing and validation of wireless and mobile health technologies. It offers the chance for transformational changes in the way we diagnose and treat a wide range of conditions.”

Vantage Health is developing personalized and point-of-care screening using Apps based upon chemical sensing residing within a small device attached to a smartphone. STSI’s Center for Digital Medicine is committed to helping in the development and research of novel mobile health devices to accelerate their uptake into clinical practice.

https://www.businesswire.com/news/home/20140210005836/en/Vantage-Health-Scripps-Translational-Science-Institute-form

NanoSpectrometer Biomarker Discovery and Confirmation Study
Sponsor:
Johns Hopkins University
Collaborator:
Nanobeak Inc.
Information provided by (Responsible Party):
Johns Hopkins University

Lung Cancer
Diagnostic Test: Breath Analysis
Brief Summary:
This study will evaluate exhaled volatile organic compounds (VOC's) in the breath of participants with stage 1 lung cancer, their house-mates, and matched controls. The goal of the study is to identify VOC fingerprints that are only detectable in those with stage 1 lung cancer.

Detailed Description:
Lung cancer is by far the leading cause of cancer death in the United States. More people die annually of lung cancer than of colon, breast, and prostate cancers combined. Worldwide it is already the leading cause of cancer death among males, and with smoking rates substantially higher in developing countries relative to the United States the worldwide burden of lung cancer is projected to increase considerably in the future.

For lung cancer, as for many cancers, early diagnosis allowing for full resection offers the greatest chance for long-term survival, but unfortunately these individuals currently constitute only a minority of the lung-cancer population. Screening technologies that allow for the earliest detection of lung cancer would therefore have tremendous potential to substantially improve outcomes. Recently, and for the first time, a screening test for lung cancer of high risk individuals has been recommended by the US Preventive Services Task Force, as well as others, for the reduction of lung cancer mortality. This recommendation was based primarily on the results of the National Lung Screening Trial (NLST) that randomized over 53,000 individuals considered at high risk for lung cancer to 3 annual screenings with either low-dose CT (LDCT) or a chest x-ray and then followed for a median of 6.5 years. In this study LDCT scanning was associated with a statistically significant 20% relative decrease in lung cancer mortality, and a smaller, but still significant 6.7% decrease in overall mortality. Despite these encouraging results of LDCT, as a screening tool it has substantial limitations. Beyond the costs, inconvenience and radiation exposure associated with LDCT, its performance characteristics are far from optimal. For example, nearly a quarter of the LDCT population had a positive screening test, with the vast majority - 96.4% - proving to be false-positive. With a positive predictive value of <4% LDCT screening will lead to a great number of unnecessary diagnostic procedures as well as substantial anxiety in the screened population and their family.

Breath analytics is a new and very promising tool for diagnosing lung cancer, as well as multiple other conditions. Previous studies identified that dog's heightened olfactory senses were able to detect cancer in an individual's breath with an accuracy of nearly 100%. Since then attempts have been made to mimic canine capabilities with "electronic noses" to detect and quantitate the nearly 3000 compounds, many in the parts per billion or even parts per trillion ranges, in exhaled breath. Early studies of these technologies support great potential as a diagnostic and screening tool. As a screening tool it could be ideal as it is noninvasive, painless and free of any undesirable side effects. In addition, new advances in nanotechnology have allowed these extremely sensitive detection technologies to be miniaturized to the point that they can be linked to a smartphone, providing future possibilities to almost continuously surveil individuals for the development of lung cancer and other life-threatening conditions. This study is concerned with comparing the concentrations of volatile organic compounds (VOCs) in the breath of lung cancer patients (cases) and lung-cancer-free individuals (controls).

Study Type : Observational
Actual Enrollment : 332 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: NanoSpectrometer Biomarker Discovery and Confirmation Study
Actual Study Start Date : September 5, 2017
Actual Primary Completion Date : July 6, 2020
Actual Study Completion Date : July 6, 2020

https://clinicaltrials.gov/ct2/show/NCT03275688


Tom Joyce

Chairman Of The Board at Nanobeak, Inc.
Darien, Connecticut
https://www.linkedin.com/in/tomjoyce1/

Chairman of the Board and interim CEO
Company Name Nanobeak Biotech, Inc.
Dates Employed Jul 2019 – Present


Location Greater New York City Area

Nanobeak is an emerging life sciences company that has developed a breathalyzer that can detect drugs in one's system. As well, it can identify certain early stage cancers. The intellectual property is from an exclusive license with NASA and had been further developed with John Hopkins University.

So Check out this about the CEO!!!

Tom Joyce
Former Chairman and CEO
Company Knight Capital Group
Dates Employed May 2002 – Jul 2013
Employment Duration 11 yrs 3 mos

PUBLISHED TUE, JUN 23 20204:39 PM EDT

Thomas Joyce, former CEO of high-speed trading firm Knight Capital Group, resigned from the Darien, Connecticut, police commission after a complaint to town leaders about his Twitter posts! Joyce currently is interim CEO of Nanobeak Biotech, a life sciences company.

Joyce, who served as Merrill Lynch’s head of U.S. equities earlier in his career, resigned as CEO of Knight Capital in July 2013, shortly after the firm was taken over by another high-speed trading company, Getco.


That takeover came nearly a year after a software glitch caused Knight to buy unwanted positions in nearly 150 stocks, leading to a whopping $440 million loss.

In the past year, Joyce became chairman and then interim CEO of Nanobeak Biotech, which specializes in mobile noninvasive disease detection.

Nanobeak currently has a reimbursable Space Act Agreement for the development of gas sensor technology with the federal space agency NASA, according to government records. The value of that agreement was not immediately available, a NASA spokesman for the agency’s Ames Research Center told CNBC.

In April, 2020 Nanobeak announced that it had terminated its founder and then-chief science officer and board member Jeremy Barbera for undisclosed reasons.


A press release about the move noted that Joyce, among his roles at the biotech firm, also is “currently on the Board of Blackstone / GSO Secured Lending fund, a business development company managed by a Blackstone affiliate.”

https://www.cnbc.com/2020/06/23/nanobeak-biotech-ceo-quits-police-board-over-muslim-profiling-tweets.html

So what do know also happened in April 2020??

Mr. Katzaroff stated, "I am delighted to lead the Company and our team forward as Poverty Dignified and Sun Ovens continues expanding its business plan. It is my intention to assist the Company and Sun Ovens to further penetrate the marketplace while actively searching to add to our portfolio of opportunities and reviewing several interesting and timely possibilities."

Here is that opportunity that got it's start back in April:

VIR EXIT
Filed: April 3, 2020
On-line retail store services featuring a wide range of cleaning and sanitizing products, hand wipes, soaps, cleaners, disinfectants…
Owned by: Patrick Netter
Serial Number: 88859111

https://trademarks.justia.com/owners/patrick-netter-1671441/

Nanobeak Announces Termination of Jeremy Barbera
Published: Apr 22, 2020

NEW YORK, April 22, 2020 /PRNewswire/ -- Nanobeak Biotech Inc., a pioneer in mobile, non-invasive disease detection at the earliest stages, today announced that Jeremy Barbera, Board member and Chief Science Officer, has been relieved of his duties and is no longer associated with the company, as of April 3, 2020. Thomas M. Joyce will continue as interim CEO. Mr. Joyce has served as Chairman of the Nanobeak Board of Directors since July 2019 and as Interim CEO of the Company since October.

Mr. Joyce brings decades of executive leadership experience to Nanobeak. In addition to sitting on the boards of a number of private companies, he is currently on the Board of Blackstone / GSO Secured Lending fund, a business development company managed by a Blackstone affiliate. Prior to that, he spent 11 years as Chairman and CEO of Knight Capital Group. He spent the earlier part of his career at Merrill Lynch, where he was responsible for a series of businesses in its global institutional equity division.

"We are focused on delivering a device that can both save lives and millions of dollars across healthcare and law enforcement," said Mr. Joyce. "When completed, the technology will allow medical professionals to rapidly screen for stage one cancer using only a patient's breath and provide law enforcement the ability to determine in real time the presence of legal and illegal drugs."

The Company recently completed a stage 1 lung cancer clinical trial at Johns Hopkins University and is currently in the analysis phase of that study.

About Nanobeak Biotech

Leveraging proven, NASA technology, Nanobeak Biotech, Inc is focusing on developing mobile, non-invasive drug and disease detection at the earliest stages. Applications will primarily be in the life sciences industry around the detection of early stage cancers and the drug/law enforcement sector.

https://ih.advfn.com/stock-market/stock-news/82282599/nanobeak-announces-termination-of-jeremy-barbera


However in spite of Jeremy being terminated he still claims employment on his LinkedIn page as well as his .com profile page?

Jeremy Barbera


Chairman and CEO at Nanobeak Biotech
New York, New York

Jeremy Barbera is a serial technology entrepreneur specializing in the development and implementation of disruptive innovative technologies. He has more than thirty years of expertise in healthcare, media, entertainment, counterterrorism, homeland security, biotechnology and nanotechnology.

https://www.linkedin.com/in/jeremybarbera/

A Physicist with a Master of Science from New York University and later a Master of Business Administration from MIT, Jeremy Barbera first started and led a company in the entertainment industry, Marketing Services Group, Inc., and another focusing on counterterrorism and homeland security, MSGI Security Solution, Inc.

Early in his career, Jeremy worked as a Research Scientist at NASA, working specifically on Pioneer Venus and the Global Atmospheric Research Program. His relationship with NASA would prove to be hugely beneficial with his work today at Nanobeak.

“Imagine parents regularly testing themselves and their children at home with this new technology. Putting this power in peoples’ hands will keep them from discovering the presence of a disease when it is too late, like stage 3 lung cancer. The Sensor will lead to early screening and early treatment, a tremendous opportunity.”

Outside of the massive implications a product of this nature can provide to the healthcare industry, it can also make a great impact on law enforcement. The Sensor will have the ability to catch the existence of marijuana on a driver’s breath. This will become increasingly more important as new states begin to legalize the substance for recreational use.

http://jeremybarbera.net/


About Jeremy Barbera
Jeremy Barbera is the CEO and Chairman of Nanobeak.

Jeremy Barbera studied at New York University (1980 – 1985) where he received a BS and MS in Physics. He would later attend MIT Sloan School Management (1994 – 1996) obtaining his MBA.

While studying at New York University, at only 23 years of age, Jeremy began work as a Research Scientist at NASA Goddard Space Flight Center, where he worked on Pioneer Venus Project as well as the Global Atmospheric Research Program.

In 1988, Jeremy Barbera founded Marketing Service Group, Inc. (MSGI), a company specializing in integrated marketing, database marketing, analytics, customer acquisition and retention. At its zenith, MSGI employed more than 1,200 employees and was name one of the top 100 companies to work for in New York City.


Jeremy Barbera is Founder of Nanobeak. He devoted much of his time learning molecular biology as he observed an opportunity for existing NASA technologies to fix real-world issues. More importantly, Jeremy feels that medicine and treatment is based on cattle herd mentality, with everyone being treated the same way, utilizing a process of elimination that is very inefficient. Nanobeak, embodies the ideals of patient centered health care, as it makes the experience of diagnosing a patient more personalized, less intrusive, and quicker.

Using NASA technology and a proprietary breathalyzer, the health screening process gets cut down tremendously and treatment becomes more easily identifiable. Imagine breathing into a device that could inform you if you are developing stage 1 cancer or heart disease on the spot, in real time. Under Jeremy’s guidance, Nanobeak is on the cusp of delivering a health benefit that could disrupt the healthcare industry in a monumental way.
http://jeremybarbera.com/